Document is current
Any future updates will be listed below
-
Authors
Sultan, Hussein
Fesenkova, Valentyna I.
Addis, Diane
Fan, Aaron E.
Kumai, Takumi
Wu, Juan
Salazar, Andres M.
Celis, Esteban
-
Funding
Funding for this research was provided by:
National Cancer Institute (R01CA136828)
National Cancer Institute (R01CA157303)
Georgia Research Alliance (Endowed Chair)
- License Information
-
More Information
Article History
Received: 27 January 2016
Accepted: 23 March 2016
First Online: 6 April 2016
Compliance with ethical standards
:
: Esteban Celis has filed patent applications based on the use of synthetic peptides and poly-IC combinatorial vaccines. The rights of the patent applications have been transferred to the Moffitt Cancer Center (Tampa, FL). Andres Salazar is President and CEO of Oncovir, Inc., who is developing poly-ICLC (Hiltonol™) for the clinic. Hussein Sultan, Valentyna Fesenkova, Diane Addis, Aaron Fan, Takumi Kumai, and Juan Wu declare no conflict of interest.
